Gastrointestinal cancer

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gastrointestinal cancer
Classification and external resources
Specialty oncology
ICD-10 C15 - C26

Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction (leading to difficulty swallowing or defecating), abnormal bleeding or other associated problems. The diagnosis often requires endoscopy, followed by biopsy of suspicious tissue. The treatment depends on the location of the tumor, as well as the type of cancer cell and whether it has invaded other tissues or spread elsewhere. These factors also determine the prognosis.

Overall, the GI tract and the accessory organs of digestion (pancreas, liver, gall bladder) are responsible for more cancers and more deaths from cancer than any other system in the body.[1][2] There is significant geographic variation in the rates of different gastrointestinal cancers.[1]

Upper digestive tract[edit]

Esophageal cancer[edit]

Age-standardised death rates from esophageal cancer, as reported by the WHO in 2004.[3]
Main article: Esophageal cancer

Esophageal cancer is the sixth-most-common cancer in the world, and its incidence is increasing.[4] Some three to five males are affected for each female.[4] An "esophageal cancer belt," in which the incidence of esophageal squamous cell carcinoma (SCC) is more than a hundred times that of adjacent areas, extends from northeastern China through central Asia to northern Iran.[1] Ethiopia also has a notably high incidence.[4] There are two main types of esophageal cancer—adenocarcinoma and squamous cell carcinoma. Worldwide, the incidence of each type is about the same, but in developed countries like North America and Europe adenocarcinoma is the more common.[4]

Cancer of the esophagus is often detected late inasmuch as there are typically no early symptoms. Nevertheless, if the cancer is caught soon enough, patients can have a five-year survival rate of 90% or above. By the time esophageal cancer is usually detected, though, it might have spread beyond the esophageal wall, and the survival rate drops significantly. In China, the overall five-year survival rate for advanced esophageal cancer is about 20%, and in the United States it is about 15%.[4]

Stomach cancer[edit]

Main article: Gastric cancer

Cancer of the stomach, also called gastric cancer, is the fourth-most-common type of cancer and the second-highest cause of cancer death globally.[2] Eastern Asia (China, Japan, Korea, Mongolia) is a high-risk area for gastric cancer, and North America, Australia, New Zealand and western and northern Africa are areas with low risk.[5] The most common type of gastric cancer is adenocarcinoma, which causes about 750,000 deaths each year.[6] Important factors that may contribute to the development of gastric cancer include diet, smoking and alcohol consumption, genetic aspects (including a number of heritable syndromes) and infections (for example, Helicobacter pylori or Epstein-Barr virus) and pernicious anemia.[1][6]

Pancreatic cancer[edit]

Salivary glands Parotid gland Submandibular gland Sublingual gland pharynx Tongue Esophagus Pancreas Stomach Pancreatic duct Ileum Anus Rectum Vermiform appendix Cecum Descending colon Ascending colon Transverse colon Colon (anatomy) Bile duct Duodenum Gallbladder Liver oral cavity
Upper and Lower human gastrointestinal tract
Main article: Pancreatic cancer

Pancreatic cancer is the fifth-most-common cause of cancer deaths in the United States,[7] and the seventh most common in Europe.[8] In 2008, globally there were 280,000 new cases of pancreatic cancer reported and 265,000 deaths.[9] These cancers are classified as endocrine or nonendocrine tumors. The most common is ductal adenocarcinoma.[1] The most significant risk factors for pancreatic cancer are advanced age (over 60) and smoking.[7] Chronic pancreatitis, diabetes or other conditions may also be involved in their development.[2] Early pancreatic cancer does not tend to result in any symptom, but when a tumor is advanced, a patient may experience severe pain in the upper abdomen, possibly radiating to the back.[7] Another symptom might be jaundice, a yellowing of the skin and eyes.[8]

Pancreatic cancer has a poor prognosis,[2] with a five-year survival rate of less than 5%. By the time the cancer is diagnosed, it is usually at an advanced, inoperable stage.[8] Only one in about fifteen to twenty patients is curative surgery attempted.[10] Pancreatic cancer tends to be aggressive, and it resists radiotherapy and chemotherapy.[9]

Liver cancer[edit]

People get liver cancer (also called hepatocellular carcinoma, HCC or hepatoma) typically from a prolonged Hepatitis B or C infection or as a result of cirrhosis from chronic alcoholism. Liver cancer may bring about yellowing of the skin and eyes (jaundice), itching (pruritis), or cause a buildup of fluid in the abdomen (ascites). A person may feel an enlarging mass, or the cancer might be revealed by abnormal liver function tests.[11]:664–666

An attending practitioner might order a biopsy, an MRI or a CT scan, and a patient might be monitored through blood tests (including alpha-fetoprotein, liver-function tests or ultrasound. These cancers are typically treated according to their TNM stage and whether or not cirrhosis is present. Options include surgical resection, embolisation, ablation or a liver transplant.[12]:969–970

Gallbladder cancer[edit]

Main article: Gallbladder cancer

Cancers of the gallbladder are typically adenocarcinomas, and are common in elderly women. Gallbladder cancer is strongly associated with gallstones, a porcelain gallbladder appearance on ultrasound, and the presence of polyps within the gallbladder. Gallbladder cancer may manifest with weight loss, jaundice, and pain in the upper right of. It is typically diagnosed with ultrasound and staged with CT. The prognosis for gallbladder cancer is poor.[12]:981

Other[edit]

Lower digestive tract[edit]

Colorectal cancer[edit]

Example of an invasive colorectal cancer.
Main article: Colorectal cancer

Colorectal cancer is a disease of old age: It typically originates in the secretory cells lining the gut, and risk factors include diets low in vegetable fibre and high in fat. If a younger person gets such a cancer, it is often associated with hereditary syndromes like Peutz-Jegher's, hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis.[11]:619–620 Colorectal cancer can be detected through the bleeding of a polyp, colicky bowel pain, a bowel obstruction or the biopsy of a polyp at a screening colonoscopy. A constant feeling of having to go to the toilet or anemia might also point to this kind of cancer.[12]:911

Use of a colonoscope can find these cancers, and a biopsy can reveal the extent of the involvement of the bowel wall. Removal of a section of the colon is necessary for treatment, with or without chemotherapy. Colorectal cancer has a comparatively good prognosis when detected early.[12]:911–912

Anal cancer[edit]

Main article: Anal cancer

An important anatomic landmark in anal cancer is the pectinate line (dentate line), which is located about 1–2 cm from the anal verge (where the anal mucosa of the anal canal becomes skin).[13] Anal cancers located above this line (towards the head) are more likely to be carcinomas, whilst those located below (towards the feet) are more likely to be squamous cell carcinomas that may ulcerate. Anal cancer is strongly associated with ulcerative colitis and the sexually transmissible infections HPV and HIV. Anal cancer may be a cause of constipation or tenesmus, or may be felt as a palpable mass, although it may occasionally present as an ulcerative form.[14]:580

Anal cancer is investigated by biopsy and may be treated by excision and radiotherapy, or with external beam radiotherapy and adjunctive chemotherapy. The five-year survival rate with the latter procedure is above 70%.[14]:580

Gastrointestinal carcinoid tumor[edit]

A gastrointestinal carcinoid tumor is a rare, slow-growing form of cancer that affects certain cells in the lining of the stomach and intestines. The cells it affects make hormones that regulate the production of digestive juices and muscles that move food through the stomach and intestines. This kind of cancer usually occurs in the appendix, small intestine, or rectum. Its presence is associated with an increased risk of cancers affecting the other parts of the digestive system. It is usually treated with surgery.[15]

Field defects[edit]

A ‘‘field defect’’ or ‘‘field cancerization’’ is a region of tissue that precedes and predisposes to the development of cancer. Field defects occur in progression to gastrointestinal tract cancers.[16] These field defects may contain visible gross manifestations, epigenetic alterations and/or mutations.

Esophagus[edit]

Adenocarcinomas of the esophagus tend to arise in a field defect called Barrett's esophagus, a red patch of tissue in the generally pink lower esophagus. A diagnosis of Barrett’s esophagus is confirmed by a metaplastic change of the esophageal mucosa from squamous to columnar mucosa with intestinal metaplasia. Barrett's esophagus is the dominant pre-malignant lesion of esophageal adenocarcinoma,[17] and has prevalent epigenetic alterations.[18]

Esophageal squamous-cell carcinomas may occur as second primary tumors associated with head and neck cancer, due to field cancerization (i.e. a regional reaction to long-term carcinogenic exposure).[19][20] A field defect associated with progression towards squamous cell carcinoma can be identified with epigenetic markers.[21]

Stomach[edit]

Gastric cancer develops within areas (field defects) of the stomach with atrophic gastritis and intestinal metaplasia: these lesions represent the cancerization field in which (intestinal-type) gastric cancers develop.[22] In one study, the field defect was clearly demonstrated in gastric carcinogenesis using miRNA high throughput data from normal gastric mucosa (from patients who had never had a gastric malignant neoplasm), non-tumor tissue adjacent to a gastric cancer, and gastric cancer tissue. Greater than 5-fold reductions were found in four miRNAs in tumor-adjacent tissues and gastric cancers as compared to those miRNA levels in normal gastric tissues.[23]

Large intestine[edit]

Longitudinally opened freshly resected colon segment showing a cancer and four polyps. Plus a schematic diagram indicating a likely field defect (a region of tissue that precedes and predisposes to the development of cancer) in this colon segment. The diagram indicates sub-clones and sub-sub-clones that were precursors to the tumors.

When a segment of the large intestine, containing a cancer, is removed, the area adjacent to the cancer (and removed with it) may show additional neoplasia in the form of polyps (see image). This is visual evidence of a field defect. Some of these polyps may be premalignant neoplastic tumors. As shown by Hofstad et al.,[24] when polyps are allowed to remain in the colon and are observed for three years, about 40% of polyps are seen to grow larger, likely progressing towards cancer. Luo et al.[25] summarized the substantial body of evidence that field cancerization occurs in the colon, often due to aberrant DNA methylation.

References[edit]

  1. ^ a b c d e Yamada T, Alpers DH et al. (2009). Textbook of gastroenterology (5th ed.). Chichester, West Sussex: Blackwell Pub. pp. 603, 1028. ISBN 978-1-4051-6911-0. OCLC 404100761. 
  2. ^ a b c d Bjelakovic, G; Nikolova, D; Simonetti, RG; Gluud, C (Jul 16, 2008). "Antioxidant supplements for preventing gastrointestinal cancers.". The Cochrane database of systematic reviews (3): CD004183. doi:10.1002/14651858.CD004183.pub3. PMID 18677777. 
  3. ^ "Death and DALY estimates for 2004 by cause for WHO Member States (Persons, all ages)". WHO. Retrieved 12 October 2013. 
  4. ^ a b c d e Yang, S; Wu, S; Huang, Y; Shao, Y; Chen, XY; Xian, L; Zheng, J; Wen, Y; Chen, X; Li, H; Yang, C (Dec 12, 2012). "Screening for oesophageal cancer.". The Cochrane database of systematic reviews 12: CD007883. doi:10.1002/14651858.CD007883.pub2. PMID 23235651. 
  5. ^ Bennett, C; Wang, Y; Pan, T (Oct 7, 2009). "Endoscopic mucosal resection for early gastric cancer.". The Cochrane database of systematic reviews (4): CD004276. doi:10.1002/14651858.CD004276.pub3. PMID 19821324. 
  6. ^ a b O'Connor, A; McNamara, D; O'Moráin, CA (Sep 23, 2013). "Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer.". The Cochrane database of systematic reviews 9: CD009322. doi:10.1002/14651858.CD009322.pub2. PMID 24062262. 
  7. ^ a b c Arcidiacono, PG; Calori, G; Carrara, S; McNicol, ED; Testoni, PA (Mar 16, 2011). "Celiac plexus block for pancreatic cancer pain in adults.". The Cochrane database of systematic reviews (3): CD007519. doi:10.1002/14651858.CD007519.pub2. PMID 21412903. 
  8. ^ a b c Moss, AC; Morris, E; Mac Mathuna, P (Apr 19, 2006). "Palliative biliary stents for obstructing pancreatic carcinoma.". The Cochrane database of systematic reviews (2): CD004200. doi:10.1002/14651858.CD004200.pub4. PMID 16625598. 
  9. ^ a b Gurusamy, Kurinchi Selvan; Kumar, Senthil; Davidson, Brian R; Fusai, Giuseppe; Gurusamy, Kurinchi Selvan (2012). "Resection versus other treatments for locally advanced pancreatic cancer". doi:10.1002/14651858.CD010244. 
  10. ^ Gurusamy, Kurinchi Selvan; Allen, Victoria B; Kalia, Amun; Davidson, Brian R; Gurusamy, Kurinchi Selvan (2011). "Diagnostic accuracy of laparoscopy for assessing the resectability in pancreatic and periampullary cancer". doi:10.1002/14651858.CD009323. 
  11. ^ a b Robbins basic pathology (8th ed.). Philadelphia: Saunders/Elsevier. 2007. ISBN 978-1-4160-2973-1. OCLC 804094752. 
  12. ^ a b c d Davidson's principles and practice of medicine. (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. 2010. ISBN 978-0-7020-3085-7. OCLC 455157186. 
  13. ^ Bruce G. Wolff et al., eds. (2007). The ASCRS textbook of colon and rectal surgery. New York: Springer. p. 1. ISBN 0-387-24846-3. 
  14. ^ a b Harrison's principles of internal medicine. (17th ed.). New York [etc.]: McGraw-Hill Medical. 2008. ISBN 978-0-07-147692-8. OCLC 237889182. 
  15. ^ "Gastrointestinal Carcinoid Tumor". National Cancer Institute at the National Institutes of Health. Retrieved 15 October 2013. 
  16. ^ Bernstein C, Bernstein H, Payne CM, Dvorak K, Garewal H (2008). "Field defects in progression to gastrointestinal tract cancers". Cancer Lett. 260 (1-2): 1–10. doi:10.1016/j.canlet.2007.11.027. PMC 2744582. PMID 18164807. 
  17. ^ Halland M, Katzka D, Iyer PG (2015). "Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus". World J. Gastroenterol. 21 (21): 6479–90. doi:10.3748/wjg.v21.i21.6479. PMC 4458759. PMID 26074687. 
  18. ^ Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A (2012). "Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma". Int J Clin Exp Pathol 5 (5): 382–96. PMC 3396065. PMID 22808291. 
  19. ^ Priante AV, Castilho EC, Kowalski LP (April 2011). "Second primary tumors in patients with head and neck cancer". Current Oncology Reports 13 (2): 132–7. doi:10.1007/s11912-010-0147-7. PMID 21234721. 
  20. ^ Scherübl H, Steinberg J, Schwertner C, Mir-Salim P, Stölzel U, de Villiers EM (June 2008). "'Field cancerization' im oberen Aerodigestivtrakt" [Coincidental squamous cell cancers of the esophagus, head, and neck: risk and screening]. HNO (in German) 56 (6): 603–8. doi:10.1007/s00106-007-1616-7. PMID 17928979. 
  21. ^ Lee YC, Wang HP, Wang CP, Ko JY, Lee JM, Chiu HM et al. (2011). "Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers". Cancer Prev Res (Phila) 4 (12): 1982–92. doi:10.1158/1940-6207.CAPR-11-0096. PMID 21952583. 
  22. ^ Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ (2013). "Precancerous lesions in the stomach: from biology to clinical patient management". Best Pract Res Clin Gastroenterol 27 (2): 205–23. doi:10.1016/j.bpg.2012.12.007. PMID 23809241. 
  23. ^ Assumpção MB, Moreira FC, Hamoy IG, Magalhães L, Vidal A, Pereira A et al. (2015). "High-Throughput miRNA Sequencing Reveals a Field Effect in Gastric Cancer and Suggests an Epigenetic Network Mechanism". Bioinform Biol Insights 9: 111–7. doi:10.4137/BBI.S24066. PMC 4496000. PMID 26244015. 
  24. ^ Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S et al. (1996). "Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years". Gut 39 (3): 449–56. PMC 1383355. PMID 8949653. 
  25. ^ Luo Y, Yu M, Grady WM (2014). "Field cancerization in the colon: a role for aberrant DNA methylation?". Gastroenterol Rep (Oxf) 2 (1): 16–20. doi:10.1093/gastro/got039. PMC 3920999. PMID 24760232. 

External links[edit]